Pramiti Parwani recently wrote a case note for the European Journal of Risk Regulation, wherein she analyses the judgement by the Court of Justice of the European Union in the Tecfidera case. The case explores the ambit of “same global marketing authorisation” in the context of regulatory data protection period for pharmaceuticals under Article 6(1) of Directive 2001/83.